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ABSTRACT
Obesity in Alaska Natives is increasing, posing significant health risk for the development of 
associated diseases. This study examined candidate obesity genes in a set of anonymized 
Alaska Native DNA samples for loci that might predict obesity risk. DNA samples were 
divided into three groups according to body mass index: lean (BMI < 23), in-between (23< 
BMI <30), and obese (BMI > 30). Screening of 5043 base pairs from the exons of leptin 
(LEP), leptin receptor (LEPR), neuropeptide-y (NPY), and melanocortin-4-receptor (MC4R) 
yielded previously discovered SNPs in NPY and LEPR. Additionally, two known promoter 
region SNPs in NPY and Uncoupling Protein-2 (UCP2) were analyzed. SNPs were in Hardy 
Weinberg equilibrium, showed litde genetic variation between populations, and were not 
associated with BMI category. We concluded that the study lacked power to detect an 
association due to an inability to correct for variables known to affect BMI and a small 
sample size. However, this study enabled pilot studies of several SNP genotyping platforms 
and the evaluation of allele frequencies in the Alaska Native population, illuminating the 
value of known SNP genotyping vs. SNP discovery and the benefit of a direct association 
study vs. an indirect association study.
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1GENERAL INTRODUCTION 
OBESITY CONCERN IN THE ALASKA NATIVE POPULATION
Obesity and diabetes have become significant health concerns in the Alaska Native 
population with the infusion of a westernized "obesogenic" environment (French et al., 2001; 
Hill and Peters, 1998; Mouratoff et a/., 1967; Mouratoff and Scott, 1973). In pre-contact 
Alaska there was virtually no obesity in the Native population (Michael, 1967). A study by 
Mouratoff et al. showed increasing rates of obesity in the Alaska Native population between 
1962 and 1972 (Mouratoff et al., 1967; Mouratoff and Scott, 1973). Non-insulin-dependant 
diabetes mellitus was shown to be rare in 1957 and is now increasing (Mouratoff et al., 1967; 
Scott and Griffith, 1957). There is evidence that these changes may be fueled by increased 
consumption of calorie rich non-indigenous food and a decrease in physical activity 
associated with mechanization (Adler et al., 1996; Murphy et al., 1995). One of the most 
notable dietary changes is the increase in carbohydrate intake from 3% to 5% in pre- 
westemized times to 50% of total energy in 1978 (Heller and Scott, 1967; Knapp and 
Panruk, 1978; Murphy et al., 1995).
AIM OF STUDY
The aim of this study is to discover single nucleotide polymorphisms (SNPs) in candidate 
obesity genes that are informative for obesity risk in the Alaska Native population. Body 
weight is a complex condition largely affected by the interaction of environment and 
genetics (Barsh et al., 2000; Loos and Bouchard, 2003). The portion of trait variation 
described by genetic transmission, heritability, for obesity has been shown to be around 70% 
in twin studies and 50% in familial studies (Allison et al., 1996; Luke et al., 2001; Maes et al., 
1997; Stunkard et al., 1990). Familial studies have shown that there is double the risk of 
developing obesity (BMI > 30) when a genetically related family member is obese when 
compared to the risk of obesity in the whole population; the relative risk is greater when a 
family has extreme obesity (BMI > 45) (Lee et al., 1997). Genome scans of families have 
identified chromosomal regions that co-segregate with obesity but no major obesity genes 
affecting a large proportion of society have been identified (Adeyemo et al., 2003; Arya et al., 
2004; Comuzzie et al., 1997; Loos and Bouchard, 2003).
2PHYSIOLOGY OF CANDIDATE GENE PRODUCTS
This study focuses on 5 candidate genes for obesity: leptin (LEP), leptin receptor (LEPR), 
neuropeptide y (NPY), melanocortin 4 receptor (MC4R), and uncoupling protein 2 (UCP2). 
These genes have been implicated as candidate obesity genes by their genetic associations 
with body weight and by supporting knowledge of the physiology of their gene products. 
The arcuate nucleus (AN) and paraventricular nucleus in the hypothalamus have been 
identified as the areas of the brain most responsible for energy regulation. The 
hypothalamus is where the gene products of LEP, LEPR, MC4R, and NPY act in pathways 
regulating energy.
Leptin is an endocrine hormone secreted by adipocytes. It signals long-term energy supply 
by binding to leptin receptors in the hypothalamus, stimulating catabolism and inhibiting 
anabolism. Leptin binds to the leptin receptor activating janus kinases (JAK) that 
phosphorylate signal transduction and transcription (STAT) proteins (Schwartz etal., 2000). 
STAT proteins facilitate the transcription of specific gene targets, presumably related to 
energy homeostasis.
The leptin receptor is a cytokine receptor whose activation stimulates expression of 
suppressor of cytokine signalling-3 (SOCS-3) proteins that inhibit further activation of the 
by leptin (Bjorbaek et al., 1998). Leptin deficiency causes severe obesity in ob/ob mice 
(Zhang et al.9 1994).
Neuropeptide Y is a widely expressed neurotransmitter that affects energy homeostasis 
through its action in the arcuate nucleus (ARC) and paraventricular nucleus (PVN) 
(O’Donohue et al.y 1985). NPY promotes fat storage, food intake, and reduces energy 
expenditure when it is centrally administrated to the hypothalamus, resulting in obesity 
(Billington et al., 1991; Stanley et al.y 1986; Zarjevski et aL, 1993). Leptin deficiency causes 
increased expression and secretion of NPY in the hypothalamus. Ob/ob mice exhibit high 
levels of NPY expression in the hypothalamus that are attenuated by administration of leptin 
(Chua et al1, 1991; Stephens et al.y 1995).
3Activation of melanocortin 4 receptor (MC4R) by a-melanocyte-stimulating hormone via 
the melanocortin-signaling pathway results in inhibition of food intake (Cone et al^ 1996). 
MC4R is a transmembrane G-protein coupled receptor that activates a cyclic adenosine 
monophosphate (cAMP) signal pathway when a-MSH binds. MC4R mouse knockouts 
exhibit hyperphagia resulting in obesity (Huszar et al., 1997).
UCP2 is a mitochondrial uncoupling protein that is thought to dissipate the proton gradient 
across the inner mitochondrial membrane. It is homologous to UCP1, which is responsible 
for generating heat in brown fat by uncoupling respiration from ATP production. Unlike 
UCP1, UCP2 is widely expressed in white adipose tissue and skeletal muscle. There is 
evidence that UCP2 plays a role in eliminating reactive oxygen species (Echtay et al.9 2002).
4CHAPTER 1: SNP DISCOVERY IN CANDIDATE GENES FOR OBESITY IN 
WESTERN ALASKA NATIVES 
INTRODUCTION
We screened 16 exons (5043 bp) in candidate genes for obesity in 56 Western Alaska Natives 
by denaturing high performance liquid chromatography (DHPLC) and sequencing in hopes 
of finding population specific genetic risk factors for obesity. Leptin, Leptin Receptor, 
Melancortin 4 receptor, and Neurpeptide Y were examined because of evidence from case- 
control and transmission-linkage studies implementing their significant roles in weight gain 
(Bray et al., 1999; 2000; Butler et al., 1998; Chagnon et al., 1997; Chagnon et al., 1999;
Chagnon et al., 2000; Hinney et al., 2003; Karvonen et al., 2000; Li et al., 1999; Mattevi et al., 
2002). Coding regions were chosen because identification of common functional SNPs were 
of primary interest. Based on findings by Cargill et al. and Stephens et al., we expeced to find 
close to one SNP per 320 base pairs of coding DNA screened for a total of 16 SNPs, 
roughly half synonymous and half non-synonymous (Cargill et al., 1999; Stephens et al.,
2001). Results by Stephens et al. suggest that cosmopolitan SNPs will compose 82% of 
those found and the remaining 18% will be either unique to the Alaska Native population or 
shared only with related groups (Stephens et al., 2001). Of the 16 SNPs we expected to find, 
3 should have been non-cosmopolitan and 13 should have been cosmopolitan.
METHODS 
DNA Extraction
The DNA was extracted from 1-2 ml of whole blood with Qiagen’s QIAamp Blood Midi 
Kit. Samples were mixed with 100 pi of Qiagen protease, 1.2 ml buffer AL, and incubated at 
70° C for 10 min. They were vortexed with the addition of 1 ml of ethanol (96%) until 
homogenous. The lysate was applied to a QIAamp midi column and centrifuged with a 
Jouan CR412 centrifuge at 3000 rpm for 3 min. The filtrate was discarded, 2 ml of buffer 
AW1 was added to the midi column, and the samples were centrifuged at 4750 rpm for 2 
min. Without removing filtrate, 2 ml of buffer AW2 was added to the midi column. The 
samples were centrifuged at 4750 rpm for 15 min. The midi column was removed and
5placed in a clean 15 ml centrifuge tube; 200 pi of buffer AE was added to each midi column 
and let to incubate at room temperature for 5 min. Samples were centrifuged for 5 min. at 
4750 rpm. For maximum yield, an additional 200 pi of buffer AE was added to the midi 
columns and equilibrated for 5 min. The samples were then centrifuged at 4750 rpm for 5 
min. The samples were then stored at 4°C in 1.5 ml screw cap vials.
DNA Quantification
The PicoGreen assay was used to quantify DNA yield of the pre-anonymized samples. 
PicoGreen DMSO stock solution was diluted 200-fold with TE. A standard curve was made 
by making dilutions of lambda DNA from a 2 pg/ml stock solution. The lambda dilutions 
(100 pi) were mixed with 100 pi of working stock PicoGreen and incubated for 5 min. at 
room temperature in the dark. Lambda concentrations for making the curve were 1 pg/ml, 
.8 pg/ml, .6 pg/ml, .4 pg/ml, .2 pg/ml, .1 pg/ml, .01 pg/ml, and .001 pg/ml. Calf thymus 
DNA at 50 pg/ml, as determined by absorbance at 260 nm, was used as a positive control. 
From each sample, 1 pi was diluted with 99 pi of TE and 100 pi of PicoGreen working 
solution. Fluorescence intensity was read with Molecular Devices Analyst AD. Excel was 
used to fit a line through standard dilution points and the equation of the line was used to 
calculate the concentrations of the samples.
The concentrations of the anonymized samples were determined using the Spectra Max plate 
reader at 260 nm absorbance. Each well contained 10 pi of sample and 90 pi of dH20 .
Beer’s Law was used to calculate the concentration of DNA based on the absorbance at 260 
nm. Dilutions of calf thymus DNA were used as positive controls. Working sample 
concentrations of 10 ng/pi were made in microtiter plates. The diluted samples were used 
for all PCRs.
6PCR Amplification
Three different PCR mixes were used to amplify target DNA, depending on the locus (Table
1.1). Unless noted to the contrary, PCR primer sequences were attained from Drs. Wendy 
Chung and Rudy Leibel at Columbia University. Touchdown PCR was used to minimize 
mispriming (Don et aL, 1991). Using Taq Gold polymerase, samples were denatured for 9 
min. at 95° C, followed by 10 cycles of 95° C for 30 sec. (denaturation), 65° C for 30 sec. -  
l°/cycle (annealing), and 72° C for 30 sec. (extension); Samples were then cycled 25 times at 
95° C for 30 sec., 55° C for 30 sec., and 72° C for 30 sec, finishing with a 6 minute extension 
at 72° C. Core mix was distributed with the Qiagen Biorobot 8000 and template was added 
with an eight-channel pipet.
PCR products were screened for individuals heterozygous for SNPs with the Transgenomic 
WAVE using DHPLC. The WAVE consists of a separatory column resting within a 
precisely controlled oven with a UV detector attached at the end. The separation cartridge is 
composed of polystyrene-divinylbenzene (PS-DVB) copolymer beads. The mobile phase is 
a mixture of triethylammonium acetate (TEAA) and acetonitrile. TEAA is an ion-pairing 
reagent whose hydrophobic ethyl component interacts with the PS-DVB beads while its 
positively charged ammonium acetate component is attracted to the negative phosphate 
backbone of nucleic acids. The TEAA connects nucleic acids to the column. Acetonitrile 
breaks the interaction between the column the TEAA and the nucleic acid. Increasing the 
amount of acetonitrile serves to elute the nucleic acids.
SNP Discovery using DHPLC
SNP discovery was performed using partially denaturing conditions under the mode 
“mutation detection.” The average temperature range for partially denaturing conditions 
was 52-75° C. In this temperature range, fragments are separated on the basis of size and 
sequence. SNP discovery is dependent on the formation and separation of heteroduplexes 
from homoduplexes. Heteroduplexes are formed by the mispairing of parent strands.
7Table 1.1 PCR Mix Concentrations derived from Ruth Stafford (R), Dr. Kevin McCracken 
(DM), and Dr. McCracken’s difficult (DMD) PCR mix.
Reaction
components
R concentrations DM concentrations DMD
concentrations
dHzO - - -
10 X PCR Gold 
reaction Buffer
IX IX IX
2.5 mM dNTPs .1 mM .25 .3
25 mM MgCl2 1.75 mM 2.5 mM 3.0 mM
5 U/pi Taq Gold 1.56 U/50 pi 
reaction
1.25 U/50 pi 
reaction
1.5 U/ 50 pi 
reaction
10 pM forward 
primer
.4 pM .5 pM .6 pM
10 pM reverse 
primer
.4 pM .5 pM .6 pM
10 ng/ pi Template 
DNA
15-30 ng 15-30 ng 15-30 ng
8Mispairing of parent strands may be induced by mixing samples with a wild type or if the 
sample being analyzed is at least diploid and heterozygous. Heteroduplex formation was 
facilitated by denaturing PCR products at 95°C for five min. and lowering the temperature to 
25° C at a rate of 0.1° C/4 sec. (Schmitt et al.).
The sequence of the PCR product was entered into the WAVE’s Navigator software to 
generate predicted fragment melt profiles based on temperature. The temperature in the 
program was adjusted to make the amplicon have a helical fraction between 70% and 85%, 
the range at which SNPs are optimally resolved (Schmitt et al.). Although, SNPs should be 
detected when the helical fraction is between 30% and 98%, as long as greater than half the 
fragment has a helical content above 50%. The predicted melt profile generated by the 
Navigator software gives the user an idea of what temperatures might detect SNPs in what 
region of the fragment but temperatures were still empirically optimized based around what 
temperatures appeared most promising in the melt profile. Fifteen exons in four candidate 
obesity genes were screened in 56 Alaska Native samples with DHPLC (Table 1.2). Exon 2 
of MC4R was screened by sequencing because it was double the length of the suggested 
optimal amplicon screening size and contained many different melting domains. Experience 
with DHPLC screening of the similarly sized MC4R exon 1 prompted the change in 
screening method for MC4R exon 2. When a heteroduplex was detected two homozygotes 
and two heterozygotes were sequenced to characterize the SNP responsible for the 
heteroduplex.
PCR products were cleaned for sequencing reactions using the Qiaquick PCR purification kit 
or with the Qiagen Biorobot 8000 along with the Qiaquick Multiwell PCR Purification kit 
(Qiagen, 2002; 2002). For the cycle sequence reaction, 2 pi of Big dye, 3 pi of purified PCR 
product, 0.3 pi of 10 mM primer, and 4.7 pi of dH20  were added for a total reaction volume 
of 10 pi. The cycle sequencing protocol was 96° C for 1 min. followed by 24 cycles at 96° C 
for 10 sec., 50° C for 5 sec., and 60° for 4 min.
9Table 1.2 Obesity Candidate Gene Exons Screened for SNPs by DHPLC and Sequencing
Ainplicon Forward Primer Reverse Primer Length of 
Ainplicon
DHPL 
C SNP 
Screen 
Temp, 
in
Celsius
Optimal 
DHPLC 
Temp, in 
Celsius
Sequence 
Verification 
of SNP
LEP ex 2 AAGAAGCCCATCCT
GGGA
GCTGGCTGCAGTTC
TACTTTG
209 60,
60.2,
60.5
LEP ex 3a CCACATGCTGAGCA
CTTGTT
TGGCAGCTCTTAGA
GAAGGC
250 61,61.3
LEP ex 3b TGGAGAACCTCCG
GGATCT
GTTCCTTCCCTTAA
CGTAGTCC
251 61.6,
64.6
LEPR ex 1 TCCACAGACAACTT
ATATATATGTG
GCTAAAGGCAAAAT
CTCTACCATG
193 55.2,
53.7,
56.7, 
57.2
LEPR ex 2a TCAGATACTTTCTA
TTCATGTCTTAGT
ATAAGTTAGAAAA
GTGAGTACCACTTG
279 52.5, 
56, 57
LEPR ex 2b AATTCGAATGGACA
TTATGA
GTATCAAAGAATTA
AAAAACATTGTTC
252 52.4,
54.4, 
57.1
LEPR ex 3 TTTTTTTTGTTTTTT
C
TAAAAAAACTGTGT
ATTAGAAATGC
205 54
LEPR ex 4 TCCTGCTTTAAAAG
CCTAATCCAGTATT
T
AGCTAGCAAATATT 
TTT GT AAGC AAT
367 52.5, 
57, 58
58 YES
LEPR ex 5 GACTTTATTTTATT
CAGCTATAATTGT
GCAGAGGGTAATT
GCTATGGGAC
300 52.8,
54.8, 
55.8
54.8 NO
LEPR ex 7a GGCAGTGTAACTCT
GGAAGTGTTGT
AGTACACTGCATCA
TAGGTAAACT
343 59.9
LEPR ex 7b ATCTATAAGAAGGA
AAACAAGATTGT
GGACTCTAATATAA
GGAGGGTCCAT
305 56.8
NPY ex 1 GCGCGTGGGTGCT
CTGAATC
GGATCTCCTGGTGT
GCAGGCAC
301 66.2,
63.2,
64.8
66.2 YES
NPY ex 2 TGCTTCATACACCT
AGCTTG
TTCATCCTCATTTCT
GCCGA
364 55.4,
59.5, 
61.5
59.5 YES
NPY ex 3 CTTCAGATCTAAAT
GTCTCAC
AGTGGCTGCATGC
ATTGGTAG
188 59,
59.4, 
59.8, 60
MC4R ex 1 ATCAATTCAGGGG
GACACTG
GACAGCACTACTAT
CTGAGT
614 57.8,
58.3,
60.9
MC4R ex 2 ATGCTCTCCAGTAC
CATAACA
TGCAGAAGTACAAT
ATTCAGG
622
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Samples were cleaned via a Millipore multiscreen filter plate sephadex G-50 spin column 
(Millipore, 2004). A 96 well aluminum block was filled with sephadex G-50 and a plastic 
scraper was used to level the wells. The Millipore filter plate was placed upside down on the 
block and then flipped to fill the sephadex into the plate. Water (300 pi) was added to each 
well and the plate was let to sit for 2-3 hours. The plate was then spun at 1000 RCF for 5 
min. An additional 150 pi of water was added to the plate and was spun again at 1000 RCF 
for 5 min. Cycle sequencing products were added to the columns and the plate was spun for 
5 min. at 1000 RCF. The collection plate containing the purified products was then 
incubated for 15 min. at 90° C to evaporate the water. Samples were stored at -20° C in the 
dark until they were ran on an Applied Biosystem 3700 Automated Sequencer. Prior to 
reading, 15 pi of formamide was added to each well, and the samples were denatured at 95° 
C for 5 min. and then placed on ice.
After sequencing, the SNPs were looked up in dbSNP and characterized using a NCBI 
index. NCBI indexes SNPs in dbSNP by two different accession numbers. The “rs[NCBI 
SNP ID]” accession number refers to the NCBI reference SNP cluster identifier, and it is 
attached to all records associated with the locus. The “ss[Assay Id]” refers to the individual 
submission record. We used the “rs” accession number because it is inclusive of all records 
associated with the site.
Phenotype
Body-mass index (BMI) is equal to the weight of an individual in kg divided by the square of 
their height in meters. BMI was used to divide samples into three categories: lean (BMI < 
23), in-between (23< BMI <30), and obese (BMI >30). From each population, 13 lean, 41 
in-between, and 21 obese were selected for SNP screening of candidate obesity gene exons. 
Samples had to have a minimum of 10 pg of DNA for use in the study. Because they were 
not originally collected for genetic research, samples were de-identified on individual and 
population levels in accordance with the University of Alaska Fairbanks Institutional Review
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Board’s criteria for use of the samples for human genetic research. Chosen samples were 
transferred to 4 unmarked boxes containing 75, screw-top, 1.5 ml, skirted tubes labeled “L” 
for lean, “I” for in-between, and “O” for obese. Two people not associated with the study 
mixed the tubes within each box. The box tops were then labeled A, B, C and D. Two 
people not associated with the study de-identified the boxes. The tubes were then labeled 
with a number, corresponding to their de-identified box top. In this procedure, all 
identifiers were removed (except for BMI class) and samples were anonymized according to 
individual and village.
RESULTS
A total of 5043 base pairs were screened. Out of 16 amplicons screened, SNPs were 
detected in LEPR exons 4 and 5 and NPY exons 1 and 2 (Figure 1.1). The DHPLC 
detected SNP in LEPR exon 5 was the only SNP that sequencing did not verify. The 
sequences of the other SNPs showed that they were not newly discovered or exclusive to the 
Alaska Native population: NPY exon 1 rs5573 (A/G), NPY exon 2 rs5574 (C/T), and 
LEPR exon 4 Glu223Arg rsl 137101 (A/G). None of the NPY SNPs cause an amino acid 
change.
DISCUSSION 
Comparison of SNP finds with other studies
Including the non-sequence verified SNP in LEPR exon 5, 1 SNP per 1.3 kb of coding 
region DNA screened were found. This is considerably less than might be expected, based 
on other studies. Stephens et al. found 1 SNP per 294 bp of coding region screened when 
they studied 313 human genes in 82 ethnically diverse individuals (Stephens et a l, 2001). The 
results of Haluska et al. were similar to Stephens et a l in that they found 1 SNP per 225 bp of 
coding region screened when they examined 75 candidate genes for blood pressure 
homeostasis in 74 humans of African and Northern European descent (Halushka et al.y 
1999). Cargill et a l reported a ratio of 1 SNP per 346 bp coding DNA screened when
12
Figure 1.1 DHPLC chromatographs for LEPR ex4 SNP (A), LEPR ex5 SNP (B), NPY 
exlSNP (C), and NPY ex2 (D). The heteroduplex is the far left peak(s). Elution window 
width: 2-4 min. for A, 2-4.5 min. for B, 4-6 min. for C, and 2.3-2.7 min for D.
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they studied 106 genes associated with cardiovascular disease, endocrinology and 
neuropsychiatry in 57 individuals of European, African-American, African Pygmie, and 
Asian descent (Cargill et al., 1999).
Reasons for lower frequency of SNP finds
Why did we find a lower frequency of SNPs in the coding regions of genes examined? The 
answer lies in sampling only one ethnic group, screening fewer genes (bps), and missing 
SNPs. The majority of human SNPs are cosmopolitan but by studying one population, W. 
Alaska Native population, we excluded the possibility for detection of SNPs specific to other 
populations (Stephens et al., 2001). Sampling a small number of base pairs made it more 
likely that the ratio of SNPs detected to base pairs screened was a fluctuation away from the 
expected. We expect that screening a greater number of base pairs would cause the SNP 
frequency to approach those found by Haluska et al., Cargill et al., and Stephens et al. Non­
detection of SNPs could have occurred because they are rare, fixed, or missed due to 
methodological screening error. It is likely that some of the SNPs are rare or fixed due to 
the reduced genetic diversity in the Alaska Native population (Budowle et al., 2002; Shields et 
al., 1993). The DHPLC screening methods were partially tested by sequencing 14 
individuals for 4 amplicons that showed no heteroduplexes. The sequence data agreed with 
the DHPLC, showing no individuals heterozygous for SNPs. Since all amplicons negative 
for heteroduplexes were not congruendy screened with sequencing we are not able to 
definitively say whether the DHPLC screen method did or did not miss SNPs. However, 
based on reports of SNP frequencies in human exons and SNP reports specific to the exons 
screened, it is strongly suspected that not all SNPs were detected.
Expected false positive and false negative rates for DHPLC
Cargill et aL used DHPLC and variant detection arrays (VDAs) to screen 106 genes and 
confirmed SNP discoveries with sequencing. The VDAs had a false positive screening rate 
of 45%, while DHPLC had a rate of 40%. Our false-positive rate was 25% for the DHPLC
14
screen. To determine the false-negative rate, Cargill et al. sequenced 10 genes in 20 
individuals; VDA detected 34/40 SNPs found by sequencing and DHPLC discovered 46/53 
SNPs identified by sequencing. The reported false-negative rate for DHPLC is not great 
enough to explain the difference between the SNP discovery rate in our study and those 
reported by Haluska et al., Cargill et al.y and Stephens et al. but it could describe a portion of 
the difference.
Examination of exons lacking SNP finds
Exons that did not show any SNPs in the screened Alaska Native population were examined 
in dbSNP. Several SNPs reported in dbSNP were not found in the Alaska Native samples. 
Two SNPs in LEP exons 2 and 3, rs l800583 and rs3750043, were reported without any 
frequency data. No functional SNPs were found in Leptin exons 2 and 3 matching results 
by Li et al. when they studied LEP coding regions in obese women (Li et al., 1999). LEPR 
exon 2 rsl 137099 was reported in dbSNP without any frequency data, and LEPR exon 7 
rs l805134 showed a minor allele frequency of .272 in dbSNP; Celera showed the minor 
allele frequency to be .26 for Caucasians and .31 for African Americans. NCBFs dbSNP 
showed three SNPs for MC4R: rs2282556, rs229616, and rsl016862. Rs2229616 had a 
minor allele frequency of .026 in a multinational screening group. NPY had two SNPs, 
rs5575 and rs5576, in exon 3 that were not detected in the Alaska Native screen population. 
The minor allele frequencies were 0.1 and .05 respectively. For the dbSNPs lacking 
frequency data we cannot say whether we would expect to find them in the Alaska Native 
population. For the SNPs having reported minor allele frequencies greater than .10 we 
would be more apt to expect them to exist in the Alaska Native population, since common 
SNPs are usually ancient and thus cosmopolitan (Risch, 2000).
CONCLUSION
In conclusion, the frequency of SNPs per base pair is likely to increase as more candidate 
gene exons are screened. Screening more base pairs will help to overcome the stochasticity
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of sampling effects. Future SNP discovery studies will benefit from pooling Alaska Native 
DNA with Caucasian or African DNA to increase the chance of detecting SNPs fixed in the 
population. Since common SNPs are of more interest, it is not necessary to increase the 
number of individuals screened. SNPs > 10% frequency are more likely to be cosmopolitan 
and have results significant to other populations, providing support for causality of the allele 
(Risch, 2000).
Call for a change in methodology
The SNP screen results call for a change in methodology. SNP screening can be cosdy, time 
consuming, and inefficient when the results are redundant. Currendy, dbSNP contains 3.7 
million SNPs, providing plenty of options for the design of candidate gene case-control 
association studies (Jiang et aL, 2003). A more efficient study design would use previously 
charactered common functional variants to test candidate genes for association with the 
variation of a particular phenotype. Non-cosmopolitan SNPs would likely be missed by this 
method but that is of no consequence because they are likely to be rare SNPs arising from 
recent mutations. Use of common SNPs would be beneficial because study results could be 
compared to other populations. Replication of results in different populations would help 
support the causality of the locus.
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CHAPTER 2: TESTING 3 NPY SNPS FOR ASSOCIATION WITH BMI IN 
WESTERN ALASKA NATIVES 
INTRODUCTION
Neuropeptide Y (NPY) has been identified as a key player in obesity pathophysiology. Lack 
of NPY in ob/ob-NPY-/NPY- double knockouts attenuates the obesity syndrome observed 
in ob/ob single knockouts (Erickson et al.,1996). Intercranial infusion of NPY increases 
feeding and reduces metabolic rate in rats (Kotz et al., 1998; Stanley et al., 1986; Stanley and 
Leibowitz, 1984). Familial linkage and case-control studies have further implemented NPY 
as a candidate gene for obesity in human populations (Bray et al., 1999; 2000; Karvonen et al., 
2000).
Bray et al. used sibling pair linkage analysis for microsattelites close to NPY to test for 
obesity linkage in 59 Mexican-American families (170 obese sibling pairs out of 545 total 
pairs); they found significant linkage within sibling pairs (Bray et al., 1999). Bray et al. then 
investigated polymorphisms in the promoter and coding regions of NPY by sequencing, 
finding a significant association between -8801/D and body fat patterning in a non-obese 
(BMI less than 30) subsample of Mexican-Americans (Bray et al., 2000). Evidence of familial 
linkage along with the reported significant association of the -8801/D variant facilitated the 
decision to investigate NPY variants in the Alaska Native population.
In this case-control study of the Western Alaska Native population, we tested for association 
of 3 NPY SNPs with BMI, with the hypothesis that the SNPs are associated with BMI 
category by being in linkage disequilibrium (LD) with a causative allele. Linkage 
disequilibrium is the nonrandom association of genetic markers in a population. Our aim 
was to determine whether any or all-3 NPY SNPs genotyped may be informative for risk of 
obesity in the Western Alaska Native population.
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METHODS
Three NPY SNPs were genotyped with three different methods because some methods 
worked better than others, depending on the locus. SBEX was used to genotype the 
population for rs5573, a synonymous SNP in the first exon of NPY. DHPLC was used to 
genotype rs5574, a synonymous SNP in the second exon of NPY. Finally, ABPs Assay on 
Demand C 11164478_20 was used to genotype NPY rsl6478, a SNP 5’ to the transcription 
start site of NPY. The program Genepop was used to calculate the Hardy-Weinberg exact 
test and Fwc(st).
SBEX uses fluorescently labeled dye terminators to extend a primer by a single base, the 
SNP of interest. The dye is either R110 or Tamara. Fluorescence polarization (FP) is used 
to discriminate between incorporated and non-incorporated nucleotide fluorescence. 
Molecules are excited using plane-polarized light. If a molecule is excited by plane-polarized 
light then the light it emits is also polarized (Perrin, 1926). FP is proportional to molecular 
volume and weight; larger molecules emit greater FP than smaller molecules. A dye 
terminator attached to the end of a primer emits a greater amount of polarized light than an 
unattached dye terminator (Figure 2.1). FP is independent of fluorescence intensity because 
it measures the ratio of polarized light in the vertical and horizontal fields.
Samples were amplified via PCR prior to the SBEX using Perkin Elmer’s suggested PCR 
concentrations (Table 2.1). Touchdown PCR conditions were used, as specified in chapter 
1. A SBEX primer (forward 5’-GGAGGACATGGCCAGATACTACTC-3’) adjacent to 
rs5573 was ordered from Qiagen. Perkin Elmer’s AcycloPrime-FP A/G SNP detection kit 
(ACPI 01 A) was used for the SBEX. PCR products were purified using 2 pi of Perkin 
Elmer’s IX PCR clean-up reagent. The clean-up reagent was added to 5 pi of PCR product 
and incubated in a Tetrad DNA engine at 37° C for 60 min. followed by 15 min. at 80° C, 
inactivating the enzyme. The cleaned PCR product was added to 13 pi of core SBEX mix in 
a black MJ Hardshell skirted plate and cycled at 95° for 2 min followed by 50 cycles of 95° 
for 15 sec and 55° for 30 sec. (Table 2.2).
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Figure 2.1 Principle of fluorescence polarization (Chen et al., 1999).
Table 2.1 Perkin Elmer PCR Conditions for Samples
Reaction components pi per reaction [Final]
h 2o 12.475
10X PCR Gold buffer 2 1
10 mM dNTPs 0.2 100
25 mM MgCl2 1.4 1.75
5  U /| jl1 AmpliTaq Gold 0.125 0.625 units
10 pM forward primer 0.4 0.2
10 pM reverse primer 0.4 0.2
10 ng/ pi template DNA 3 15-25ng
Total 20
Table 2.2 SBEX Core Mix
Reagent pl/rxn
Acyclopol .05
lOXRxN Buffer 2
Acyclo terminator mix 1
SNP primer (10 uM) 0.5
Water 9.45
Total volume 13
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The Molecular Devices Analyst AD was used to read polarized fluorescence of the SBEX 
reaction. Samples were first read with the R110 filter (ex. 490-10 and em. 520-10) and then 
read with Tamara (ex. 550-10 and em. 580-10). Both reads were saved to the same file so 
they could be opened with the program Allele Caller. Allele Caller creates a visual 
representation of the FP values for each sample. Each axis represents FP associated with a 
particular base.
The WAVE was used to genotype NPY exon 2 rs5574. Buffer A was 5% .1M TEAA and 
buffer B is 5% .1M TEAA and 25% acetonitrile. The WAVE was set for mutation detection 
with the oven temperature set at 59.5° C. The gradient (%B per min.) was set at 2 and 
started at 56.3% B and ended at 65.3% B.
An Assay on Demand, C_11164478_20, was used to genotype 58 samples from population 
B for a SNP (rsl6478) 5’ of the transcription start site of NPY. Each reaction had a core 
mix consisting of 9.25 pi of H20 , 12.5 pi of 2X Taqman PCR master mix, and 1.25 pi of 
SNP genotyping assay mix. The Qiagen Biorobot 8000 was used to distribute 23 pi of core 
mix to each well and 2 pi of Template was added manually. Samples were incubated at 95°
C for 10 min. and then cycled 40 times at 92° C for 15 sec. followed by 60° C for 1 min.
The samples were then covered with adhesive foil and sent to Applied Biosystems. They 
were read as an endpoint assay on the Taqman.
RESULTS
The SBEX reaction for NPY exonl rs5573 yielded distinct genotype groupings for all 
populations: A, B, C, and D (Figure 2.2). The genotypes were totaled and divided according 
to their respective BMI group (Table 2.3). Genepop was used to test the locus for Hardy- 
Weinberg equilibrium and to calculate Fwc(st) (Table 2.4). Fst is a F-statistic developed by 
Sewall Wright to measure the amount of population subdivision and the reduction of 
heterozygosity. It compares the heterozygosity expected in a total population to the
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Figure 2.2 SBEX genotyping of population A for NPY rs5573.
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Table 2.3 NPY Exon 1 A/G SNP, rs5573, Genotype Frequencies Determined with SBEX.
Phenotype AA AG GG T otals
Lean 42 4 2 48
In-between 103 30 3 136
Obese 60 8 1 69
Totals 205 42 6 253
Table 2.4 Hardy-Weinberg Test and Fwc(st) for NPY SNPs.
SNP Degrees of 
freedom
^2 statistic 
for Hardy- 
Weinberg 
Probability 
test
Probability Fwc(st)
rsl 6478 
promoter
2 — .27 (ns) —
rs5573 ex 1 8 9.54 .30 (ns) .0012
rs5574 ex 2 8 7.4 .49 (ns) .0240
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mean heterozygosity across all subpopulations. Low levels of gene flow should yield higher 
Fst values. The probability of fit as being worse by chance was >.05; so, the Hardy- 
Weinberg model cannot be rejected. The Fwc(st) statistic was <.05, showing little 
population differentiation between populations A, B, C, and D, with respect to the locus 
(Wright, 1978).
Associations between rs5573 and obesity were tested under additive and non-additive 
models using ^-distributed test statistics. A trend test was used to model the effect of an 
additive allele, and both a genotype case-control statistic and a G-test of independence were 
used to model nonadditive effects (Table 2.5). A trend test compares the increment of the 
likelihood of having a phenotype between heterozygotes and homozygotes. If the 
likelihood of having the phenotype is significantly similar then the hypothesis that the locus 
is associated with the trait in an additive manner is supported. The G-test of independence 
tests the goodness of fit of observed and expected values (Sokal and Rohlf, 1995). G-tests 
have a higher level of type I errors (rejection of a true null hypothesis); so, William’s 
correction factor is applied to better model the chi-square distribution (Williams, 1976). We 
cannot reject the null hypothesis that the genotype at rs5573 is independent of BMI 
grouping. The minor allele frequency of 0.11 was much lower than those reported for other 
ethnic groups (Table 2.6).
The WAVE yielded distinct genotypes for NPY exon 2 rs5574 that were tallied and grouped 
according to BMI group (Figure 2.3 and Table 2.7). Genepop was used to test whether the 
population was in Hardy-Weinberg equilibrium for rs5574. The chi-square test resulted in a 
P-value >.05; so, the hypothesis that the population was in Hardy-Weinberg equilibrium 
could not be rejected (Table 2.4). Fwc(st), calculated using Genepop, was .024, showing 
little genetic differentiation between subpopulations (Table 2.4). Tests for independence of 
BMI group from rs5574 genotype were not significant for both additive and nonadditive 
models. The minor allele frequency, .44, is close to the .376 reported by dbSNP in a multi­
ethnic sample set (Table 2.6).
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Table 2.5 ^2-distributed Test Statistics for Independence of Genotype from Phenotype in 
NPY SNPs.
SNP Sample size Trend test Non- G-test with
for additive additive x2 William’s
allele using statistic correction
only Obese (4df) (4 df)
and Lean
rs16478 37 5.9*10A-5 4.2 4.06
promoter (ns) (ns) (ns)
rs5573 ex 1 253 1.3*10A-3 7.39 7.09
(ns) (ns) (ns)
rs5574 ex 2 271 l.l*10A-5 1.56 1.53
(ns) (ns) !ns) ..............
Table 2.6 NPY Minor allele frequencies.
Caucasian
(Celera)
Chinese
(Celera)
Japanese
(Celera)
African
American
(Celera)
Multi­
ethnic
(dbSNP)
Alaska
Native
Promoter 
rs16478
.29 — — .36 — .09
Exon 1 
rs5573
.5 .44 .38 .32 .317 .11
Exon 2 
rs5574
— — — .376 .44
Table 2.7 NPY Exon 2 C/T SNP, rs5574, Genotype Frequencies Determined with DHPLC.
Phenotype CC CT TT Totals
Lean 14 15 19 48
In-between 45 36 67 148
Obese 25 21 29 75
Totals 84 72 115 271
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Figure 2.3 WAVE Chromatogram of the Separation of NPY ex2 SNP 
Heteroduplex and Homoduplexes.
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Figure 2.4 displays results for the genotyping of NPY promoter SNP, rsl6478, and Table 2.8 
shows the genotype counts for each BMI group. The P-value for the Hardy-Weinberg test 
was >.05; so, the hypothesis that the population is in Hardy-Weinberg may not be rejected. 
The hypothesis that the NPY promoter SNP is independent of BMI category could not be 
rejected for both additive and non-additive models (Table 2.5). The minor allele, A, 
frequency was .09, which was much less than other ethnic groups (Table 2.6).
DISCUSSION
Hardy-Weinberg could not be rejected, lending support to the idea that the populations are 
randomly mating. One study showed that villages used to be smaller with much inter-village 
movement; they were located within 62 miles of two other villages and roughly half of 
mothers and fathers did not live in their birthplace (Scott and Wright, 1983). Genetic data 
shows that the Alaska Native population has lower genetic diversity when compared to 
Caucasians and Africans, and they have little genetic differentiation among subpopulations 
(Budowle et al., 2002; Shields et al., 1993). Our data support previous findings with low 
Fwc(st) values. Although mating is unlikely to be totally random, the demographic and 
genetic data suggest that there is enough homogeneity between the Alaska Native villages 
studied to combine allele frequency data from the 4 populations for the tests of 
independence of SNP genotype from BMI group.
The minor allele frequencies for the NPY exon 1 and promoter SNPs were very different 
from those reported for other populations. It is interesting that the SNP in exon 2 was the 
only NPY SNP to have a minor allele frequency close to a reported value in another sample 
set. The NPY exon 2 SNP was also unique in that it had the highest Hardy-Weinberg 
probability. This raises the question of why the promoter and exon 1 SNPs have lower 
Hardy-Weinberg probabilities. It would be tempting to hypothesize that they are in LD with 
a locus affected by evolutionary forces not strong enough to be detected by the chi-square 
test for Hardy-Weinberg.
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Figure 2.4 Allelic Discrimination Plot for a NPY Promoter SNP 
Generated with Applied Biosystems Taqman.
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Table 2.8 NPY Promoter A/G SNP, rsl6478, Genotype Frequencies Determined with 
Taqman.
Phenotype AA AG GG Totals
Lean 0 0 11 11
In-between 1 4 13 18
Obese 0 1 7 8
Totals 1 5 31 37
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The null hypothesis that the NPY SNP genotype was independent of BMI group could not 
be rejected because there was either no effect of the SNP on BMI or there was not enough 
power to detect an association. It is likely that the NPY SNPs examined had no direct 
functional effect on BMI because they consisted of non-coding and synonymous changes, 
but it is plausible that they could be in LD with functional SNPs. If these SNPs were in LD 
with a functional SNP affecting obesity, it would be difficult to detect an association because 
variables known to affect BMI could not be corrected for due to the anonymization. In 
addition, if NPY carries polymorphisms of small effect, accounting for ~5% of trait 
variation, an association is not likely to be detected because our sample size was less than 
500 (Long and Langley, 1999; Palmer and Cookson, 2001). Therefore, to best increase the 
probability of detecting a SNP/phenotype association we must increase our sample size 
above 500 individuals and keep all descriptors that may affect weight so the appropriate 
statistical correction may be applied. Since we do not have any linkage disequilibrium data 
on the loci of interest in the Western Alaska Native population it would be best to choose 
common SNPs, having allele frequency data in at least one population, that alter an amino 
acid or potentially change gene expression.
Having allele frequency data indicating that a SNP is common would give confidence to the 
decision to use the SNP in an Alaska Native study. Common SNPs in one or more 
populations are more likely to be common in other populations. Even though this set of 
Alaska Native DNA samples has indicated that some of their SNP frequencies are different 
from other study populations, all of the NPY SNPs have minor allele frequencies large 
enough to be considered common. A benefit of using common SNPs is the ability to 
compare results between different populations.
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CHAPTER 3: TESTING UCP2 -866 A/G, rs659366, FOR ASSOCIATION WITH 
BMI IN WESTERN ALASKA NATIVES 
INTRODUCTION
UCP2 is widely expressed and codes for a mitochondrial uncoupling protein (Gimeno et al., 
1997; Jaburek et al., 1999). UCP2’s role in energy expenditure and heat production and its 
close proximity to microsatalite markers linked to resting energy expenditure in humans 
provides support of the classification of UCP2 as a candidate obesity gene (Boss et al., 2000; 
Bouchard et al., 1997). Evans et al. found a positive association of a 45 bp insertion in UCP2 
and morbid obesity, and Esterbauer et al.. detected an association of a common UCP2 
promoter region SNP, rs659366, with decreased risk of obesity in humans of Bavarian and 
Austrian German descent, increased mRNA expression, and increased reporter gene 
expression (Esterbauer et al., 2001; Evans et al., 2000; Evans et al., 2001).
We wanted to test for the —866, rs659366, association with BMI category in the W. Alaska 
Native population. Detection of the association would provide support to the hypothesis 
that the locus describes a portion of BMI variation in human populations. Non-rejection of 
the null hypothesis could imply that the association is population specific, Esterbauer et al. 
study had erroneous results due to cryptic underlying population substructure, or that our 
study design lacked the power to detect the association.
METHODS
UCP2 rs659366 was genotyped using SBEX and the Molecular Devices Analyst AD. PCR 
cycling conditions and R mix concentrations were used, as described in chapter 1. PCR 
primers were designed using the Saccharamyces Genome Database web primer design 
program; the forward primer sequence is 5’-GGGAATCCGTTTCCTCATTGT-3’, the 
reverse primer is 5’- TGAGAAAAGGCGTCAGGAGAT-3’, and the SBEX forward primer
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is 5’- TGAGAAAAGGCGTCAGGAGAT-3’ (Dolinski et al., 2003). The SBEX reaction 
was carried out according to methods described in chapter 2.
RESULTS
The SBEX reaction of UCP2 —866 yielded distinct genotype groupings that were then tallied 
according to BMI group (Figure 3.1 and Table 3.1). The hypothesis that the population was 
in Hardy-Weinberg equilibrium could not be rejected because the Hardy-Weinberg 
probability test yielded a P-value >.05 (Table 3.2). The Fwc (st) indicated that there was 
little genetic variation between the four villages, with a value < .05 (Table 3.2). The minor 
allele is “G” and the frequency was .39. A multi-ethnic sample set from dbSNP showed “A” 
to be the minor allele with a frequency of .333. All tests for independence for both additive 
and non-additive models were not significant (Table 3.3). The null hypothesis that the 
genotype at UCP2 —866 is independent of BMI group could not be rejected.
DISCUSSION
Previous findings show that the UCP2 —866 A allele increases transcription of UCP2, is 
associated with decreased obesity risk, and is associated with increased glucose oxidation and 
decreased lipid oxidation in European populations (Esterbauer et al., 2001; Krempler eta/., 
2002; Le Fur et at\, 2004). Our results differ, in that they do not show an association 
between the —866 variant and BMI. We may not have been able to detect an association of — 
866 and BMI because of small sample size, the inability to correct for variables affecting 
BMI, and a weak genetic effect of the locus (Hirschhom et al., 2002). Alternatively, the 
associations of the —866 variant with obesity and increased lipid oxidation may only exist in 
the European population, from which they were reported. An area of concern with 
Esterbauer et al., study is that there was no control for possible underlying population 
stratification. Populations were said to be mostly of Barvarian and Austrian descent but the 
idea that their results could be confounded by genetic admixture was not addressed.
Spurious allelic association has been implicated in studies such as Knowler et al., study on the
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Figure 3.1 SBEX genotyping of population B for UCP2 -866.
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Table 3.1 UCP2 Promoter A/G SNP, rs659366, Genotype Frequencies Determined with 
SBEX.
Phenotype AA AG GG Totals
Lean 16 27 7 50
In-between 51 65 18 134
Obese 22 28 12 62
Totals 89 120 37 246
Table 3.2 Hardy-Weinberg Test and Fwc(st) for UCP2 -866.
SNP Degrees of 
freedom
y2 statistic 
for Hardy- 
Weinberg 
Probability 
test
Probability Fwc(st)
rs659366 8 14.5 .07 (ns) .0108
Table 3.3 ^-distributed Test Statistics for Independence for UCP2 -866 rs659366.
SNP Sample size Trend test Non­ G-test with
for additive additive yr William’s
allele using statistic correction
only Obese (4df) (4df)
and Lean
rs659366 246 9.0*10A-3 1.86 1.78
(ns) ............ (ns) H ......................
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HLA haplotype and diabetes in the Pima Indian population and in Blum et al., study on the 
dopamine DRD2 allele and alcoholism (Blum et al., 1990; Gelemter et al., 1993; Knowler et 
al., 1988). These studies may be the exception not the rule. Wacholder et al., showed that 
population stratification bias is rare and could be accounted for by proper inquires to 
people’s ethnic origins (Wacholder et al., 2000). We must genotype greater than 500 Alaska 
Native’s with more refined phenotypes, correcting for variables affecting obesity, in order to 
support or refute the UCP2 —866 A allele association with decreased risk of obesity in the 
Alaska Native population.
It is interesting that the Alaska Native sample set had “G” as the minor allele, while “A” is 
the minor allele in the multi-ethnic sample set. A study done by Sesti et al., suggested that 
the -866 polymorphism plays a role in the variation of insulin secretion; they found that 
islets from AA homozygotes had a lower insulin response to glucose administration 
compared to the other genotypes (Sesti et al., 2003). Since “A” is the major allele in the 
Alaska Native sample set, it might prove illuminating to test whether the same association 
exists.
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CHAPTER 4: TESTING LEPR A/G RS1137101 FOR ASSOCIATION WITH BMI 
IN WESTERN ALASKA NATIVES 
INTRODUCTION
LEPR has been implemented as a candidate gene for obesity by both transmission-linkage 
and case-control studies (Chagnon et al., 1999; Chagnon et al., 2000; Mattevi et al., 2002). A 
mutation in LEPR has been shown to cause severe obesity in humans and several Lepr 
mutation mouse models exhibit early-onset obesity (Clement et al., 1998). LEPR has been 
cloned and mapped to lp31 (Chung et al., 1996; Tartaglia et al., 1995).
The common polymorphism, LEPR Gln(CAG)223Arg(CGG), rsl 137101, has exhibited 
both linkage and case-control association with BMI in multiple human studies (Chagnon et 
al., 1999; Chagnon et al., 2000; Mattevi et al., 2002). The polymorphism lies in a Cytokine 
domain that is a possible binding site for leptin (Tartaglia et al., 1995). Chagnon et al. 
hypothesized that altering the amino acid at position 223 could change the leptin receptor’s 
signaling capacity (Chagnon et al., 2000). In this case-control study rsl 137101, Gln223Arg, 
was tested for its association with BMI in the Western Alaska Native population. The null 
hypothesis is that the genotype is independent of BMI category.
METHODS
75 Alaska Native samples were PCR amplified and sequenced with LEPR exon 4 reverse 
primer, described in Chapter 1. Hardy-Weinberg was tested with Genepop. A trend test 
(additive), chi-square (non additive), and G test of independence (non additive) were used to 
test the null hypothesis that the genotype at the locus is independent of BMI group.
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RESULTS
Hardy-Weinberg could not be rejected with a probability of .69 that the difference between 
the observed and expected was due to chance (Table 4.1). The null hypothesis that the locus 
is independent of BMI could not be rejected in any of the chi-square test statistics (Table
4.1). The minor allele, A, in the sample set had a frequency of .18, considerably lower than 
other reported minor allele frequencies at the locus (Table 4.2).
DISCUSSION
No departures from the Hardy-Weinberg assumptions were large enough to be detected by 
the chi-square test. This lends support that, with respect to this locus, evolutionary forces 
are negligible and that the population is randomly mating. The minor allele frequency of the 
sample set is considerably lower than those reported by Celera and dbSNP for Caucasian, 
African American, and multi-ethnic groups; this highlights the uniqueness of the Alaska 
Native population and reiterates the importance of continuing genetic study. The SNP is 
still considered to be “common” even though the Alaska Native samples had a lower minor 
allele frequency than the other groups. The definition of a common allele is somewhat 
arbitrary and ranges from a minor allele frequency >1% to a minor allele frequency >10% 
(Cargill et al., 1999; Risch, 2000).
The tests for association could not reject the null hypothesis that BMI category is 
independent from the locus. This may mean that the locus is not associated with BMI or 
that there was not enough power to detect an association in the sample set. Since the sample 
set was de-identified, variables known to affect BMI could not be corrected. The sample 
size was 72 which is much less than Long and Langley’s recommended 500 or greater (Long 
and Langley, 1999). Future studies will greatly benefit from increased sample size, sample 
information pertinent to BMI, and acquisition of refined phenotypes. LEPR rsl 137101 
remains a candidate locus for contributing to the development of obesity. Continuing
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Table 4.1 LEPR G/A, rsl 137101, ^-distributed Test Statistics for Independence and
Hardy-Weinberg equilibrium.
SNP Sample size Hardy- Trend test Non­ G-test with
Weinberg for additive additive %2 William’s
Probability allele using statistic correction
(Idf) only Obese (4df) (4df)
and Lean
rsl 137101 72 .69 (ns) 1.01*10^-6
H
7.32
(ns)
7.57 
(ns) _
Table 4.2 LEPR G/A SNP, rsl 137101, Minor Allele Frequencies.
Caucasian African Multi-ethnic Alaska
(Celera) American (dbSNP) Native
(Celera)
Minor allele (A) 
frequency
.48 .42 .34 .18
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studies in the Alaska Native population, as well as others, will help determine how much of a 
role the locus has in the etiology of obesity.
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GENERAL CONCLUSION 
SNP DISCOVERY
Fewer SNPs were "discovered” than expected based on previous studies of SNPs in coding 
regions. This is most likely attributed to the stochastic nature of sampling a small number of 
base pairs (5043), sampling a single population having increased homogeneity, and missing 
SNPs. Increasing the number of coding base pairs screened would likely cause the ratio of 
SNP per coding base pair screened to approach those reported by Cargill et al. and Stephens 
et al. (Cargill et al., 1999; Stephens et al., 2001).
SNPs found were previously characterized in other populations. This is not surprising given 
that most human variation is cosmopolitan (ancient origin) and only 20% is either 
population specific or shared between related populations. Therefore, it would be more 
economical to use common known SNPs for fine mapping over candidate gene regions or 
for functional mapping. Since we’ve shown that Alaska Natives can have very different 
allele frequencies than other populations, the following question arises: How do we know 
SNPs that are common in other populations are common in the Alaska Native population? 
All 5 SNPs genotyped in the Alaska Native population had minor allele frequencies >5%.
As was mentioned in chapter 2, the definition of “common” is somewhat arbitrary, ranging 
from minor allele frequencies >1% to >10%. Researchers often use the intermediate 
definition of “common” as meaning the minor allele frequency is >5%. If we adopt this 
same definition, then all 5 SNPs studied are common in the Alaska Native population, 
despite being different in frequency than other populations.
HARDY-WEINBERG, FST, AND TESTS FOR ASSOCIATION WITH BMI
Hardy-Weinberg could not be rejected for all loci studied, and rs5573, rs5574, and UCP2 - 
866 indicated little genetic differentiation between subpopulations by Fwc(st) values <.05 
(Wright, 1978). The null hypothesis that genotype is independent of BMI group could not 
be rejected for any of the loci. In particular, previously reported associations with BMI for
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the UCP2 promoter SNP and the LEPR SNP were not supported using this sample set.
This could mean that there is no association between the SNPs and BMI in the Alaska 
Native population or there was not enough power to detect an association. To increase 
power, variables known to affect BMI, such as age and sex, would need to be corrected for 
and the sample size would need to be increased (Long and Langley, 1999).
NON-REPLICATION OF CASE CONTROL ASSOCIATION STUDIES
Non-replication of case-control association studies is not surprising. Hirschhom et al. 
reviewed 600 association studies that reported positive associations and found that only 6 
had been consistently replicated three or more times (Hirschhom et al1, 2002). They then 
discussed possible causes of false positive and false negative association reports. Possible 
causes of false positive results were listed as population stratification from ethnic admixture, 
variation of LD with causative variant, and gene-gene or gene-environment interactions 
specific to a certain population. Hirschhom et al. said that underpowered studies along with 
weak genetic effects are most likely the cause for falsely negative associations. The results of 
our study could very well lie in the category of falsely negative association studies for those 
reasons. Due to high non-replication levels of case-case control studies, Nature adopted 
stringent publication guidelines: large sample sizes, associations must make biological sense, 
small P values, initial study must be replicated, and case-control results must be supported by 
family based studies.
Few research groups are likely to fulfill all of Nature's association study guidelines. This does 
not mean that case-control association studies should not be done. Rather, it emphasizes the 
need for collaborative research. It also suggests that a database containing all association 
results, positive and negative, and enough information to perform meta-analyses would 
greatly increase the value of case-case control studies, regardless of the size of the study or 
number of guidelines fulfilled.
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UNIQUE ALLELE FREQUENCIES
The NPY exon 2 SNP was the only SNP having a minor allele frequency close to those 
reported in another sample set. The greatest difference in minor alleles was observed in the 
UCP2 -866 SNP, where the Alaska Native sample set had an alternate minor allele than the 
dbSNP multi-ethnic panel. The unique allele frequencies found in this Alaska Native sample 
set confirm the need for further genetic studies. The most probable explanation for the 
difference in allele frequencies is that the Alaska Natives underwent a series of population 
bottlenecks created by founder effects and/or by numerous epidemics. Population 
bottlenecks have been shown to increase the incidence of rare diseases in several human 
populations (Hard and Clark, 1997). The vastly different allele frequencies in the Alaska 
Native population could contribute to the susceptibility of certain diseases. If a study could 
control for the environment, allele frequencies could be compared between populations to 
test whether the unique allele frequencies found in Alaska Natives are able to explain 
increased risk of obesity.
METHODS OF SNP GENOTYPING
Different methods of SNP genotyping worked better or worse depending on the locus. 
Applied Biosystem’s assays on demand 5’ nuclease reactions were the most convenient and 
easy to use because no optimization is required. SBEX and DHPLC require optimization, 
and sequencing is too expensive for high throughput SNP genotyping. The take home 
message is that it is beneficial to have more than one SNP genotyping method. The 
International HapMap project illustrates this point by using five different genotyping 
technologies; “a SNP assay that fails on one platform may be developed successfully using 
another method in order to fill a gap in the HapMap” (Gibbs et al., 2003).
INDIRECT VS. DIRECT CASE-CONTROL ASSOCIATION STUDIES
Case-control studies looking for loci associated with the variation of a complex trait may be 
carried out in a direct or indirect manner (Collins et al., 1997). Direct case-control
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association studies test only functional variants for disease association. Functional variants 
are those that change the protein or the expression of the gene. Indirect studies use dense 
regularly spaced SNPs to cover a region of interest. A direct approach using common SNPs 
to screen candidate genes would be ideal. Advantages of choosing functional SNPs are that 
they are more likely to be responsible for the phenotypic variation of the candidate gene, 
they could narrow the number of SNPs needed to be genotyped, and that they are not 
wholly dependent on LD. Indirect studies are fully dependent upon LD; LD is highly 
variable within the human genome and between populations, creating debate over the 
number of SNPs required (Kruglyak, 1999; Risch, 2000). Additionally, LD is usually not 
complete so the genetic effect is diluted, making it more difficult to detect loci affecting the 
variation of a trait (Cardon and Bell, 2001). Ohashi and Tokunaga tested the power of 
indirect vs. direct studies to find disease loci, and they found that indirect studies have 
severely reduced statistical power (Ohashi and Tokunaga, 2001).
In future studies I would choose a direct case-control association approach using common 
functional SNPs. Functional SNPs can be divided into two categories: those causing amino 
acid changes and those putatively altering gene expression. SNPs potentially altering gene 
expression would be higher priority than those altering amino acids. Several obesity and 
diabetes studies have reported associations between common promoter region SNPs and 
variation in phenotype (Hoffstedt et al1, 2002; Muller et al1, 2003; Wang et al1, 2002; Wang et 
al1, 2004). SNPs causing amino acid changes are of lower priority because conservative 
amino acid changes are unlikely to alter the function of the protein, while large amino acid 
changes are likely to be rare and deleterious. SNPs that may alter expression would be 
further prioritized according to whether they are located in conserved promoter regions and 
how many putative transcription factor binding sites they alter. A direct case-control 
method using common SNPs potentially altering candidate gene expression has three main 
benefits over an indirect method: it reduces the number of SNPs assayed per gene, it is not 
wholly dependent on LD, and positive associations are testable for biological significance 
using functional assays.
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Before indirect or direct case-control association methods are applied it would be useful to 
conduct a genome scan in the Alaska Native population to determine the broad regions of 
the genome that are linked to obesity in the Alaska Native population. Previously 
characterized candidate obesity genes lying close to linkage peaks would be primary targets 
of study, as well as genes making biological sense.
SUMMATION
In summation, a completely anonymized sample set study design is ill advised. Too much 
sample information is lost leading to decreased statistical power. Case-control association 
studies of complex diseases often already suffer from a lack power due to there being many 
genes of weak effect and from inadequate sample sizes. If for ethical reasons a sample set 
must be anonymized the most refined phenotype should be kept, as long as it does not 
compromise the anonymity of the samples. A more refined phenotype would allow some 
statistical corrections for variables affecting the phenotype of interest
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